{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:21:42Z","timestamp":1648988502432},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.exphem.2010.04.012","type":"journal-article","created":{"date-parts":[[2010,5,3]],"date-time":"2010-05-03T06:19:50Z","timestamp":1272867590000},"page":"773-781","source":"Crossref","is-referenced-by-count":1,"title":["Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model"],"prefix":"10.1016","volume":"38","author":[{"given":"Juwon","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Im","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Hee","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Soon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Kook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Sung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2010.04.012_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.04.012_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.04.012_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2010.04.012_bib4","first-page":"2343","article-title":"The BCR gene and Philadelphia chromosome-positive leukemogenesis","volume":"61","author":"Laurent","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2010.04.012_bib5","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1038\/sj.onc.1206081","article-title":"Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML","volume":"21","author":"Druker","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2010.04.012_bib6","first-page":"M11","article-title":"Bcr-Abl inhibition as a modality of CML therapeutics","volume":"1551","author":"Buchdunger","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2010.04.012_bib7","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.04.012_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia","volume":"9","author":"Gorre","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2010.04.012_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.04.012_bib10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.04.012_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-4608(02)00615-5","article-title":"BCR\/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration","volume":"139","author":"Campbell","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.exphem.2010.04.012_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.04.012_bib13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2010.04.012_bib14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.leu.2402678","article-title":"Interleukin-3 protects Bcr-Abl transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors","volume":"16","author":"Dorsey","year":"2002","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T07:11:14Z","timestamp":1591254674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X10001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0301472X10001554"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2010.04.012","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}